Skip to content
Politically.com Search all
Menu

2025 · 1st Quarter (Jan 1 - Mar 31)

TAKEDA PHARMACEUTICALS AMERICA INC

Filed by TAKEDA PHARMACEUTICALS AMERICA, INC..

Open official filing
Source: Lobbying Disclosure APIRecently refreshed. 2026-08-03 06:26:15 UTC.

Source-reported fields

Filing overview

Type
1st Quarter - Report
Posted
Apr 22, 2025
Income
Not reported
Expenses
$490,000.00
Filing UUID
347613ce-f21e-48c4-bd7f-0b0496e922e7
Termination date
Not reported

Expense method: A

Literal source text

Lobbying issues and bill citations

BUD · Budget/Appropriations

FY 2025 Budget Resolution - Pharmaceutical Related Provisions

TAX · Taxation/Internal Revenue Code

Tax incentive issues as they relate to proposed global supply chain bills Discussions related to the repeal of the BEAT - provisions related to orphan drug tax credits Administration's Global Tax Proposal General issues around 2025 Reconciliation/Inbound Concerns

TRD · Trade (domestic/foreign)

General intellectual property policy issues Issues related to proposed tariffs - all pharmaceutical related provisions

DEF · Defense

Discussions around Supply Chain implications

MMM · Medicare/Medicaid

Policies to enhance patient access to medicines in Medicaid including rebate, waiver policy and funding issues Policies to enhance patient access to medicines in Medicare Review of proposed rule regarding testing of Medicare part B prescription drug models Proposals related to amending the protected classes in Medicare Medicare payment proposals Medicare Drug Price Negotiation Program: Selected Drugs for Initial Price Applicability Year 2026 Discussions on biosimilars related to IRA Discussions on spillover related to the IRA Medicare Drug Price Negotiation Program: Selected Drugs for Initial Price Applicability Year 2027 Medicare Drug Price Negotiation Program: Selected Drugs for Initial Price Applicability Year 2028 Discussions on reforming the Inflation Reduction Act Discussions on treatment of small molecule drugs related to IRA H.R.1 492 , S. 832, EPIC Act of 2025 H.R. 946, Optimizing Research Progress Hope and New (ORPHAN) Cures Act

Literal federal measure citations: H.R.1, S. 832, H.R. 946

HCR · Health Issues

Clarifying or reforming the 340B program Value-based drug contracting Patient access of plasma therapies Global pharmaceutical supply chain operations and manufacturing locations Most Favored Nation/International Reference Pricing Co-pay accumulators maximizers, alternate funding models Customs Border Protection changes impacting southern border plasma collections Promoting the Congressional Plasma Caucus Rare disease diagnosis and access to care Pharmacy Benefit Managers (PBMs) Drug pricing, including House and Senate draft bills H.R. 1476, S. 694, PLASMA Act H.R. 2528, Association Health Plans Act H.R. 2214, DRUG Act

Literal federal measure citations: H.R. 1476, S. 694, H.R. 2528, H.R. 2214

Relationship and amount limits

Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.